Your browser doesn't support javascript.
loading
Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
Hong, Seung-Woo; Shin, Jae-Sik; Moon, Jai-Hee; Jung, Soo-A; Koh, Dong-In; Ryu, Yeaseong; Park, Yoon Sun; Kim, Do Yeon; Park, Sang-Soo; Hong, Jun Ki; Kim, Eun Ho; Kim, Mi Jin; Jeong, Hong-Rae; Bae, In Hwan; Ahn, Young-Gil; Suh, Kwee Hyun; Cho, Ig-Jun; Kang, Jong-Soon; Hong, Yong Sang; Lee, Jung Shin; Jin, Dong-Hoon; Kim, Tae Won.
Afiliação
  • Hong SW; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.
  • Shin JS; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Moon JH; Department of Convergence Medicine, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Jung SA; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.
  • Koh DI; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Ryu Y; Department of Convergence Medicine, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Park YS; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.
  • Kim DY; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Park SS; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Hong JK; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.
  • Kim EH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Kim MJ; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Jeong HR; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Bae IH; Department of Convergence Medicine, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Ahn YG; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Suh KH; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Cho IJ; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Kang JS; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Hong YS; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Lee JS; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Jin DH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Kim TW; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Invest New Drugs ; 38(6): 1696-1706, 2020 12.
Article em En | MEDLINE | ID: mdl-32462369
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Proteínas Inibidoras de Apoptose / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Invest New Drugs Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Proteínas Inibidoras de Apoptose / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Invest New Drugs Ano de publicação: 2020 Tipo de documento: Article